A patient in Leicester rings their GP surgery on a Monday morning and is told the next routine appointment falls five weeks away. They are not alone. Across England, the average wait for a primary care appointment has stretched well past a month, and three in four adults are managing at least one chronic condition that, left unmonitored, will eventually demand more expensive treatment than early detection would have required. It is against this backdrop that an Austin-based company just persuaded General Catalyst to hand it $450 million to expand a service built entirely around skipping the GP.

Function Health lets members order their own panel of more than 160 lab tests, add MRI or CT scanning for under $1,000, and receive the results through an app rather than a referral letter. The financing, structured as non-dilutive capital tied to customer growth rather than equity, followed acquisitions of a nationwide blood draw network and a supplement platform, and it values the company at $2.5 billion. The pitch is seductive: continuous, patient-owned surveillance of one's own biology, unmediated by a system that increasingly cannot find the appointment slots to provide it.

There is no realistic prospect of an NHS equivalent scaling in the same way, and that is precisely the point worth examining. Britain does not lack the ambition. The government's 10-Year Health Plan commits the NHS to a decisive shift from treating illness to preventing it, with earlier diagnosis positioned as one of its central pillars. What the plan does not solve is where the diagnostic capacity to support that shift will come from. Radiology departments already report vacancy rates that leave routine scans queuing behind urgent cancer pathways. Direct-to-consumer testing does not create diagnostic capacity; it creates demand for it, in the form of incidental findings that require specialist interpretation, contextualisation, and often follow-up imaging that the ordering platform has no obligation to provide.

This is the mechanism worth naming plainly. A membership testing platform can flag an elevated marker or an ambiguous shadow on a scan and hand the patient a result. It cannot admit them, cannot biopsy them, cannot manage the anxiety of a false positive through a system designed to absorb exactly that kind of triage. In the United States, where Function operates, that follow-up capacity is rationed by price and insurance status. In Britain, it would land on a service that already rations by waiting list. The NHS would inherit the psychological and clinical fallout of consumer diagnostics without ever having designed or funded the pathway to manage it.

There is also a quieter argument about who gets to participate. Private testing and scanning services already operate in the UK, serving patients willing and able to pay for access that the public system cannot currently guarantee. A company built on the promise of continuous biological self-knowledge sharpens that divide rather than closing it. Those with the means to monitor themselves outside the NHS will do so; those without will continue to wait for symptoms to become severe enough to justify referral. Prevention, in that arrangement, becomes another benefit distributed by income rather than clinical need, at precisely the moment the government is promising the opposite.

None of this means the underlying instinct is wrong. Earlier detection genuinely does reduce downstream cost and suffering, and the frustration driving patients toward services like Function is a rational response to a primary care system under real strain. But policymakers watching capital flow into direct-to-consumer diagnostics should treat it as a warning about unmet demand rather than a model to import wholesale. The NHS's prevention strategy will only be credible once someone can say, with confidence, what happens after the test result arrives, who reads it, who explains it, and who pays for what comes next. Until then, the gap between what patients can order and what the health service can absorb will keep widening, and companies elsewhere will keep raising nine-figure sums to fill it.